
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4213380</article-id><article-id pub-id-type="publisher-id">176</article-id><article-id pub-id-type="doi">10.1007/s40262-014-0176-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Pediatric Microdose Study of [14C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mooij</surname><given-names>Miriam G.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>van Duijn</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Knibbe</surname><given-names>Catherijne A. J.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Windhorst</surname><given-names>Albert D.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Hendrikse</surname><given-names>N. Harry</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Vaes</surname><given-names>Wouter H. J.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Spaans</surname><given-names>Edwin</given-names></name><address><email>e.spaans@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fabriek</surname><given-names>Babs O.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Sandman</surname><given-names>Hugo</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Grossouw</surname><given-names>Dimitri</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hanff</surname><given-names>Lidwien M.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Janssen</surname><given-names>Paul J. J. M.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Birgit C. P.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Tibboel</surname><given-names>Dick</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>de Wildt</surname><given-names>Saskia N.</given-names></name><address><phone>+31 10 70 36 889</phone><email>s.dewildt@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children’s Hospital, Room Sp-3458, Wytemaweg 80, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands </aff><aff id="Aff2"><label/>TNO, Zeist, The Netherlands </aff><aff id="Aff3"><label/>Division of Pharmacology, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, Leiden, The Netherlands </aff><aff id="Aff4"><label/>Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff5"><label/>Department of Pharmacy and Clinical Pharmacology, VU University Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff6"><label/>Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>53</volume><issue>11</issue><fpage>1045</fpage><lpage>1051</lpage><permissions><copyright-statement>© The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Pediatric drug development is hampered by practical, ethical, and scientific challenges. </plain></SENT>
<SENT sid="3" pm="."><plain>Microdosing is a promising new method to obtain pharmacokinetic data in children with minimal burden and minimal risk. </plain></SENT>
<SENT sid="4" pm="."><plain>The use of a labeled oral microdose offers the added benefit to study intestinal and hepatic drug disposition in children already receiving an intravenous therapeutic drug dose for clinical reasons. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="5" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>The objective of this study was to present pilot data of an oral [14C]paracetamol [acetaminophen (AAP)] microdosing study as proof of concept to study developmental pharmacokinetics in children. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="7" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>In an open-label microdose pharmacokinetic pilot study, infants (0–6 years of age) received a single oral [14C]AAP microdose (3.3 ng/kg, 60 Bq/kg) in addition to intravenous therapeutic doses of AAP (15 mg/kg intravenous every 6 h). </plain></SENT>
<SENT sid="9" pm="."><plain>Blood samples were taken from an indwelling catheter. </plain></SENT>
<SENT sid="10" pm="."><plain>AAP blood concentrations were measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS) and [14C]AAP and metabolites ([14C]AAP-Glu and [14C]AAP-4Sul) were measured by accelerator mass spectrometry. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>Ten infants (aged 0.1–83.1 months) were included; one was excluded as he vomited shortly after administration. </plain></SENT>
<SENT sid="13" pm="."><plain>In nine patients, [14C]AAP and metabolites in blood samples were detectable at expected concentrations: median (range) maximum concentration (Cmax) [14C]AAP 1.68 (0.75–4.76) ng/L, [14C]AAP-Glu 0.88 (0.34–1.55) ng/L, and [14C]AAP-4Sul 0.81 (0.29–2.10) ng/L. </plain></SENT>
<SENT sid="14" pm="."><plain>Dose-normalized oral [14C]AAP Cmax approached median intravenous average concentrations (Cav): 8.41 mg/L (3.75–23.78 mg/L) and 8.87 mg/L (3.45–12.9 mg/L), respectively. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="15" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>We demonstrate the feasibility of using a [14C]labeled microdose to study AAP pharmacokinetics, including metabolite disposition, in young children. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>The online version of this article (doi:10.1007/s40262-014-0176-8) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></SecTag></p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer International Publishing Switzerland 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e416"><title><text><SENT sid="19" pm="."><plain>Key Points </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain> </plain></SENT>
</text></p></sec><SecTag type="INTRO"><sec id="Sec1" sec-type="intro"><title><text><SENT sid="21" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="22" pm="."><plain>Up to 70 % of drugs prescribed to children are unlicensed or off-label, which brings risk of drug toxicity or therapeutic failure [1, 2]. </plain></SENT>
<SENT sid="23" pm="."><plain>However, pediatric drug studies face important ethical, practical, and scientific challenges [3]. </plain></SENT>
<SENT sid="24" pm="."><plain>A major challenge—against the background of developmental changes in drug absorption, distribution, metabolism, and excretion—is appropriate dose selection [4]. </plain></SENT>
<SENT sid="25" pm="."><plain>Simple size- or weight-based extrapolations from adult to pediatric doses do not suffice, particularly in neonates and infants. </plain></SENT>
<SENT sid="26" pm="."><plain>Current strategies include simulations using population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models [5–9]. </plain></SENT>
<SENT sid="27" pm="."><plain>The usefulness of these models may be limited, as relatively little pediatric pharmacokinetic and physiological data are available to validate them. </plain></SENT>
<SENT sid="28" pm="."><plain>Hence, new data are needed to support these models, as well as alternative methods to collect pharmacokinetic data without the inherent risks of toxicity when a therapeutic dose is given for the first time in a specific age group. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Microdosing is an interesting alternative. </plain></SENT>
<SENT sid="30" pm="."><plain>The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) define a microdose as one-hundredth of the No Observed Adverse Effect Level (NOAEL) or predicted pharmacologic dose based on animal data or as 100 μg of the new drug, whichever dose is lower [10, 11]. </plain></SENT>
<SENT sid="31" pm="."><plain>Dose linearity between the microdose and therapeutic dose is a prerequisite to extrapolate pharmacokinetic data to dosing guidelines [12]. </plain></SENT>
<SENT sid="32" pm="."><plain>The extremely low dose concentrations call for highly sensitive measurements. </plain></SENT>
<SENT sid="33" pm="."><plain>Accelerator mass spectrometry (AMS) can measure low attomolar to zeptomolar isotope ratio ranges, to quantify [14C]labeled drug or metabolite concentrations in urine or plasma samples, even after at least five half-lives following a microdose [13]. </plain></SENT>
<SENT sid="34" pm="."><plain>[14C] Labeling of a microdose is associated with very low radiation exposure, i.e., less than 10 μSv in adults, when compared with the yearly background exposure of 2.5 mSv/year in The Netherlands [14]. </plain></SENT>
<SENT sid="35" pm="."><plain>Hence, microdosing is safe to use to study pharmacokinetics in children. </plain></SENT>
<SENT sid="36" pm="."><plain>In clinical care, [14C]urea has been safely used to test for Helicobacter pylori infection [15]. </plain></SENT>
<SENT sid="37" pm="."><plain>A [14C]ursodiol microdose study in preterm infants was briefly described in an excellent review on the potential for use of AMS in children [16]. </plain></SENT>
<SENT sid="38" pm="."><plain>Administering a labeled oral microdose to children already receiving a therapeutic drug dose for clinical reasons intravenously offers the added possibility to study oral bioavailability [12, 17]. </plain></SENT>
<SENT sid="39" pm="."><plain>This approach may also serve to delineate developmental changes in the drug-metabolizing enzymes involved in intestinal and hepatic drug metabolism [17, 18]. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>Paracetamol (acetaminophen; AAP), is much used in children and is an interesting study drug for several reasons. </plain></SENT>
<SENT sid="41" pm="."><plain>First, its metabolism shifts from primarily sulphation (AAP-sulphate [AAP-Sul]) to glucuronidation (AAP-glucuronide [AAP-Glu]) in the first year of life, as reflected by urinary metabolite kinetics [19, 20]. </plain></SENT>
<SENT sid="42" pm="."><plain>The relative contribution of intestinal and hepatic drug metabolism has not been studied to date. </plain></SENT>
<SENT sid="43" pm="."><plain>Second, dose linearity under normal conditions and after probenecid glucuronidation inhibition was shown in adults [18]. </plain></SENT>
<SENT sid="44" pm="."><plain>We therefore selected oral [14C]AAP to study the developmental changes in AAP glucuronidation and sulphation in children already receiving the non-labeled or ‘cold’ drug intravenously for analgesia [14]. </plain></SENT>
<SENT sid="45" pm="."><plain>This paper presents our first pilot data as proof of concept of this promising, safe method to study developmental pharmacokinetics in children. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2" sec-type="methods"><title><text><SENT sid="46" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="47" pm="."><plain>Study Design </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>This proof-of-concept study is part of a larger phenotyping study in 60 children delineating developmental changes in AAP to metabolite clearance (EudraCT 2011-005497-28). </plain></SENT>
<SENT sid="49" pm="."><plain>The Dutch Central Committee on Research Involving Human Subjects (The Hague, The Netherlands) approved the larger study. </plain></SENT>
<SENT sid="50" pm="."><plain>Parents or legal guardians gave informed consent. </plain></SENT>
<SENT sid="51" pm="."><plain>Radiation exposure was explained during the informed consent procedure in relation to background exposure and exposure from medical imaging. </plain></SENT>
<SENT sid="52" pm="."><plain>The Dutch Nuclear Research and Service Group estimated individual exposures at approximately 1 μSv for a 0- to 2-year-old child, well below the minimal risk category 1 (100 μSv) of the International Commission of Radiological Protection and the yearly background exposure (2.5 mSv). </plain></SENT>
<SENT sid="53" pm="."><plain>Category 1 risk studies are considered minimal risk and are allowed when they provide new scientific knowledge [11]. </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="54" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Patients admitted to the Intensive Care department of the Erasmus MC-Sophia Children’s Hospital (Rotterdam, The Netherlands) were considered for inclusion. </plain></SENT>
<SENT sid="56" pm="."><plain>Inclusion criteria were age between 0 and 6 years, gestational age &gt;36 weeks, medical need for intravenous AAP, and an indwelling central venous or arterial line in place. </plain></SENT>
<SENT sid="57" pm="."><plain>To reduce pharmacokinetic variability due to underlying disease, patients with kidney and liver injury or the use of more than one vasopressor drug were excluded, as well as children intolerant to enteral nutrition. </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="58" pm="."><plain>Study Procedures </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>A single oral [14C]AAP microdose (3.3 ng/kg, 60 Bq/kg, 0.25 mL/kg) followed by 1 mL of saline (to ensure rinsing of the enteral feeding tube) was administered in addition to the intravenous therapeutic dose of AAP (15 mg/kg intravenously every 6 h) prescribed by the treating physician to provide analgesia. </plain></SENT>
<SENT sid="60" pm="."><plain>The [14C]AAP oral dose also contained 1.7 µg/kg non-labeled AAP, but this amount was negligible in relation to the therapeutic intravenous dose and thus considered irrelevant for the pharmacokinetic estimations. </plain></SENT>
<SENT sid="61" pm="."><plain>The microdose was based on a previous adult [14C]AAP microdose study using 100 μg/7.1 kBq/individual and was normalized for weight [21]. </plain></SENT>
<SENT sid="62" pm="."><plain>Blood samples (0.5 mL) were taken from the indwelling catheter before and at 10–30 min, 1, 2, 4, 6, 12, and 24 h after dosing. </plain></SENT>
<SENT sid="63" pm="."><plain>Blood samples were centrifuged and plasma was stored at −80 °C until analysis. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="64" pm="."><plain>Medicinal Products </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>The AAP formulation (10 mg/mL) was purchased from Fresenius Kabi, Schelle, Belgium. </plain></SENT>
<SENT sid="66" pm="."><plain>[14C]AAP was purchased from Moravek Biochemicals (Brea, CA, USA). </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="67" pm="."><plain>Radiopharmaceutical Preparation </plain></SENT>
</text></title><p><text><SENT sid="68" pm="."><plain>The formulation for oral administration [14C]AAP was prepared by adding [14C]AAP to an AAP formulation for intravenous use at the good manufacturing practice (GMP) radiopharmaceutical production laboratories of the Department of Radiology and Nuclear Medicine at the VU University Medical Center (Amsterdam, The Netherlands) (GMP license no. </plain></SENT>
<SENT sid="69" pm="."><plain>NL/H 11/0005) at final concentrations of 13 ng/mL for [14C]AAP and 6.7 µg/mL for non-labeled AAP. </plain></SENT>
<SENT sid="70" pm="."><plain>The mixed formulation was passed over a Millex®-GV 0.22 µm filter and dispended in 20 mL sterile vials. </plain></SENT>
<SENT sid="71" pm="."><plain>Radiochemical purity was &gt;99 %; chemical purity &gt;98 %. </plain></SENT>
<SENT sid="72" pm="."><plain>The radiopharmaceutical was heat sterilized and was shown to be stable for 2 months. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>Non-specific binding was tested by running the [14C]AAP formulation followed by 1 mL of saline through enteral feeding tubes. </plain></SENT>
<SENT sid="74" pm="."><plain>Radioactive recovery measured by liquid scintillation was greater than 95 %. </plain></SENT>
</text></p></sec><sec id="Sec8"><title><text><SENT sid="75" pm="."><plain>Paracetamol (Acetaminophen; AAP) Analysis </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>AAP concentrations were measured in the Hospital Pharmacy laboratory of Erasmus MC with a clinically used enzyme multiplied immunoassay technique (EMIT, Abbott Laboratories, Weesp, the Netherlands) immunoassay method (Abbott Laboratories®) with a lower limit of quantification (LLOQ) of 2.8 mg/L. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="77" pm="."><plain>[14C]AAP and Metabolite Analysis </plain></SENT>
</text></title><sec id="Sec10"><title><text><SENT sid="78" pm="."><plain>Plasma Sample Extraction and Ultra Performance Liquid Chromatography Separation </plain></SENT>
</text></title><p><text><SENT sid="79" pm="."><plain>Using 175 μL 100 % v/v methanol containing 6.6 μg/mL of AAP in 96-well protein precipitation plates, 45 μL of plasma was extracted. </plain></SENT>
<SENT sid="80" pm="."><plain>The pellet was washed with 100 μL 0.9 % NaCl :100 % methanol (1:4 v/v). </plain></SENT>
<SENT sid="81" pm="."><plain>Resulting filtrates were evaporated to dryness, and re-dissolved in 30 μL 10 mM ammonium phosphate pH3.4 (Eluent A) of which 25 μL was used for ultra performance liquid chromatography (UPLC) analysis. </plain></SENT>
<SENT sid="82" pm="."><plain>An AAP solution with a specific radioactivity of 4,100 Bq [14C]AAP/100 μg AAP in blank pooled plasma was used to prepare eight calibrators levels and three quality control (QC) sample levels from 0.4 to 180 mBq/mL, and from 1.7 to 131 mBq/mL, respectively. </plain></SENT>
<SENT sid="83" pm="."><plain>Calibrators (duplicate), QCs (triplicate), and sample extracts were injected onto a UPLC coupled to a photodiode array (PDA). </plain></SENT>
<SENT sid="84" pm="."><plain>Chromatographic conditions can be found in Table 1. </plain></SENT>
<SENT sid="85" pm="."><plain>AAP in 100 % methanol was added to each collected fraction to increase the carbon-12 content to 25 μg.Table 1Ultra performance liquid chromatography conditions for paracetamol (acetaminophen) UPLC ultra performance liquid chromatography </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="86" pm="."><plain>Accelerator Mass Spectrometry Analysis </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>[14C]AAP and metabolites were determined as described recently [22]. </plain></SENT>
<SENT sid="88" pm="."><plain>A novel AMS sample introduction method was used in this study to allow the routine analysis of biomedical samples. </plain></SENT>
<SENT sid="89" pm="."><plain>The method consists of an automated carbon dioxide (CO2) combustion device online coupled to an AMS. </plain></SENT>
<SENT sid="90" pm="."><plain>Briefly, dried fractionated samples are placed in a tin-foil cup and subsequently combusted using an elemental analyzer (EA) (Vario Micro, Elementar, Germany). </plain></SENT>
<SENT sid="91" pm="."><plain>The resulting CO2 was captured on a zeolyte trap at the interface, connecting the EA to the AMS. </plain></SENT>
<SENT sid="92" pm="."><plain>CO2 was released by heating of the trap and transferred to a vacuum syringe using helium. </plain></SENT>
<SENT sid="93" pm="."><plain>The resulting 6 % v/v gas mixture of CO2 with helium was infused at a pressure of 1 bar at 60 μL/min into the titanium target in the SO110 ion source of a 1 MV Tandetron AMS (High Voltage Engineering Europe B.V., Amersfoort, The Netherlands) [23]. </plain></SENT>
<SENT sid="94" pm="."><plain>Within the source, CO2 is converted into negative carbon ions. </plain></SENT>
<SENT sid="95" pm="."><plain>The validation for the liquid chromatography (LC) + AMS analysis was based on the recommendation of the European Bioanalytical Forum. </plain></SENT>
<SENT sid="96" pm="."><plain>Three QC concentration levels were included: QC High 145 mBq/mL, QC Medium 14.5 mBq/mL, and QC Low 2.4 mBq/mL. </plain></SENT>
<SENT sid="97" pm="."><plain>The accuracy of QC High, Medium, and Low analysis corresponded to 104, 103, and 90 %, respectively. </plain></SENT>
<SENT sid="98" pm="."><plain>The precisions, defined by a coefficient of variation, were 9.1, 6.7, and 6.9 %, respectively. </plain></SENT>
<SENT sid="99" pm="."><plain>All values are well within the requirements for LC + AMS analysis [24]. </plain></SENT>
<SENT sid="100" pm="."><plain>The LLOQ of the method was 0.58 mBq/mL. </plain></SENT>
</text></p></sec></sec><sec id="Sec12"><title><text><SENT sid="101" pm="."><plain>Data Analysis </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>Data were summarized as median (range), unless noted otherwise. </plain></SENT>
<SENT sid="103" pm="."><plain>The plasma [14C]AAP and metabolite concentrations were calculated by converting measured Bq/L to ng/L based on the dose given (3.3 ng/kg contained 60 Bq/kg) and for the metabolites corrected for molecular weight ([14C]AAP 151 g/mol, [14C]AAP-Glu 237 g/mol, and [14C]AAP-4Sul 231 g/mol) To compare the disposition of oral [14C]AAP microdose with the intravenous therapeutic doses, the microdose concentrations were dose normalized to 15 mg/kg by multiplying with 5 × 10E6. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="Sec13" sec-type="results"><title><text><SENT sid="104" pm="."><plain>Results </plain></SENT>
</text></title><sec id="Sec14"><title><text><SENT sid="105" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>Between 13 January and 31 May 2014, 32 patients were eligible. </plain></SENT>
<SENT sid="107" pm="."><plain>Nine patients were excluded for logistical reasons and 13 for refusal of informed consent. </plain></SENT>
<SENT sid="108" pm="."><plain>Parents’ informed consent was received for ten patients who were subsequently dosed according to the protocol. </plain></SENT>
<SENT sid="109" pm="."><plain>One patient vomited within 15 min post-dose and was excluded from pharmacokinetic analysis. </plain></SENT>
<SENT sid="110" pm="."><plain>Table 2 provides a summary of patient characteristics.Table 2Patient characteristics aPatient 7 excluded from results after vomiting within 15 min after microdose intake </plain></SENT>
</text></p></sec><sec id="Sec15"><title><text><SENT sid="111" pm="."><plain>Detection of [14C]AAP and Metabolites in Plasma </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>Time profiles of [14C]AAP, [14C]AAP-Glu, and [14C]AAP-4Sul metabolite plasma concentrations of two representative patients are shown in Fig. 1. </plain></SENT>
<SENT sid="113" pm="."><plain>These patients were chosen as they represent the youngest and the oldest age group. </plain></SENT>
<SENT sid="114" pm="."><plain>The Electronic Supplementary Material shows graphs of all patients. </plain></SENT>
<SENT sid="115" pm="."><plain>The median time to maximum concentration (tmax) and maximum concentration (Cmax) median (range) for [14C]AAP were, respectively, 153 min (10–245 min) and 1.68 ng/L (0.75–4.76 ng/L), for [14C]AAP-Glu were 248 min (161–382 min) and 0.88 ng/L (0.34–1.55 ng/L), and for [14C]AAP-4Sul were 193 min (115–343 min) and 0.81 ng/L (0.29–2.10 ng/L). </plain></SENT>
<SENT sid="116" pm="."><plain>Sample collections were not complete for all patients as the arterial line was prematurely removed or access to the line was restricted for clinical reasons.Fig. 1[14C]AAP and metabolite plasma concentrations after an oral [14C]AAP 3.3 ng/kg dose (lower limit of quantification 0.03 ng/L). AAP acetaminophen (paracetamol), Glu glucuronide, Sul sulphate </plain></SENT>
</text></p></sec><sec id="Sec16"><title><text><SENT sid="117" pm="."><plain>Dose-Normalized [14C]AAP and AAP Disposition </plain></SENT>
</text></title><p><text><SENT sid="118" pm="."><plain>Semilog plots of the same two patients of dose-normalized 3.3 ng/kg oral [14C]AAP and 15 mg/kg every 6 h intravenous AAP concentrations are shown in Fig. 2. </plain></SENT>
<SENT sid="119" pm="."><plain>Individual graphs of all patients are displayed in the Electronic Supplementary Material. </plain></SENT>
<SENT sid="120" pm="."><plain>Dose-normalized median [14C]AAP Cmax concentrations approached median intravenous average concentrations (Cav) [median (range)]: 8.41 mg/L (3.75–23.78 mg/L) and 8.87 mg/L (3.45–12.9 mg/L), respectively.Fig. 2Dose-normalized plasma concentrations after a PO [14C]AAP (3.3 ng/kg) and IV AAP (15 mg/kg/ every 6 h) dose (dose-normalized LLOQ AMS 0.03 mg/L; LLOQ LC-MS/MS 2.8 mg/L). </plain></SENT>
<SENT sid="121" pm="."><plain>AAP IV administration timepoints are indicated with black arrows. </plain></SENT>
<SENT sid="122" pm="."><plain>Patient 6: at the latter two timepoints there was insufficient blood collected to analyze AAP concentrations in plasma. AAP acetaminophen (paracetamol), AMS accelerator mass spectrometry, IV intravenous, LC-MS/MS liquid chromatography–tandem mass spectrometry, LLOQ lower limit of quantification, PO oral </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec17" sec-type="discussion"><title><text><SENT sid="123" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="124" pm="."><plain>This proof-of-concept study shows the practical and ethical feasibility of a [14C]microdose study in children to study developmental pharmacokinetics. </plain></SENT>
</text></p><p><text><SENT sid="125" pm="."><plain>The concentrations of [14C]AAP are in the expected range, when compared with dose-normalized concentrations previously reported in neonates and children [25–27]. </plain></SENT>
<SENT sid="126" pm="."><plain>The average [14C]AAP concentrations and metabolite Cmax values are also similar to those in a previous adult study: 1.64 versus 1.68 ng/mL for [14C]AAP, 0.88 versus 0.92 ng/mL for [14C]AAP-Glu, and 0.62 versus 0.88 ng/mL for [14C]AAP-4Sul [18]. </plain></SENT>
<SENT sid="127" pm="."><plain>The apparent lack of an age-related difference in metabolite disposition is easily explained by our small sample size and the even smaller number of neonates in our cohort. </plain></SENT>
<SENT sid="128" pm="."><plain>This is supported by our observation that in the 4-day-old neonate [14C]AAP-4Sul concentrations are much higher than the [14C]AAP-Glu concentrations, while the opposite is observed in the 2.4-year-old, in line with developmental changes in AAP metabolism. </plain></SENT>
<SENT sid="129" pm="."><plain>In the follow-up study up to 50 additional patients will be included to study developmental changes in AAP disposition with enough statistical power. </plain></SENT>
<SENT sid="130" pm="."><plain>Interestingly, the average tmax values in our patients are much later than in the adult study: 0.25 versus 2.6 h for [14C]AAP, 0.25 versus 4 h for [14C]AAP-Glu, and 0.5 versus 3.2 h for [14C]AAP-4Sul. </plain></SENT>
<SENT sid="131" pm="."><plain>A possible explanation for this finding may be slower oral absorption due to maturation and the underlying critical illness or post-operative state in our patients [26, 28]. </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>The major barrier to a [14C]microdosing study in children has been the perceived risk of radiation in the context of a non-therapeutic trial [29, 30]. </plain></SENT>
<SENT sid="133" pm="."><plain>Still, radiation exposure in this study was extremely low (&lt;1 μSv), much lower than yearly background exposure (2.5 mSv/year in The Netherlands), a continental flight (&gt;4 μSv), exposure from chest X-ray (10 μSv), or computed tomography scans (100 μSv) [7, 14]. </plain></SENT>
<SENT sid="134" pm="."><plain>To overcome parental ethical barriers to the study, we added a letter from the Dutch collaborative patients’ organization for rare and genetic diseases (VSOP) to the patient information leaflet, explaining the need for pediatric drug research and the minimal risk involved in this study. </plain></SENT>
<SENT sid="135" pm="."><plain>Surprisingly, from the informed consent conversations it appeared that most parents perceived there was minimal risk involved. </plain></SENT>
<SENT sid="136" pm="."><plain>Fear for harmful radiation exposure was not the main reason to deny informed consent. </plain></SENT>
<SENT sid="137" pm="."><plain>Parents of the other children refused informed consent for reasons relating to the burden of additional procedures and/or blood sampling. </plain></SENT>
</text></p><p><text><SENT sid="138" pm="."><plain>Very sensitive LC–tandem mass spectrometry (LC-MS/MS) techniques to measure the pharmacokinetics of an unlabeled microdose may be an alternative to using a radiolabeled microdose in general [31]. </plain></SENT>
<SENT sid="139" pm="."><plain>Nevertheless, while low drug concentrations can be measured with LC-MS/MS, this analytical method has not reached the very low limits of detection of AMS. </plain></SENT>
<SENT sid="140" pm="."><plain>Hence, a larger unlabeled dose may be needed, which may increase the risk of a therapeutic or toxic effect [13]. </plain></SENT>
<SENT sid="141" pm="."><plain>Moreover, the use of an unlabeled microdose would also prohibit the separation of the disposition of an oral and intravenous dose given at the same time. </plain></SENT>
<SENT sid="142" pm="."><plain>This could be overcome by using stable isotope-labeled probe drugs, which have successfully been used to study oral bioavailability using 15N3-midazolam in adults [32]. </plain></SENT>
<SENT sid="143" pm="."><plain>This method also has the important disadvantage that a much higher labeled drug dose is needed with similar or even higher risk of therapeutic or toxic effect. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="Sec18" sec-type="conclusions"><title><text><SENT sid="144" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="145" pm="."><plain>We have shown proof of concept for the practical and ethical feasibility of a [14C]labeled microdose to study pharmacokinetics in young children. </plain></SENT>
<SENT sid="146" pm="."><plain>This approach offers innovative possibilities to perform phase I first-in-child studies, especially for drugs with a small therapeutic window and high toxicity. </plain></SENT>
<SENT sid="147" pm="."><plain>In addition, it enables studies in vulnerable populations such as critically ill neonates and studies on developmental pharmacokinetics using probe drugs for specific elimination pathways such as drug-metabolizing enzymes and renal excretion. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="148" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><sec id="Sec19"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40262_2014_176_MOESM1_ESM.docx"><caption><p><text><SENT sid="149" pm="."><plain>Supplementary material 1 (DOCX 622 kb) </plain></SENT>
</text></p></caption></media></supplementary-material></sec></sec></SecTag></body><back><SecTag type="COMP_INT"><ack><p>We would like to thank Ko Hagoort for critically reading the manuscript. This work was funded by a Netherlands Organization for Health Research and Development (ZonMw) research grant (113202007). All authors have no potential conflicts of interest to declare.</p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="150" pm="."><plain>1.SchirmETobiHde VriesTWChoonaraIDe Jong-van den BergLTLack of appropriate formulations of medicines for children in the communityActa Paediatr200392121486148910.1111/j.1651-2227.2003.tb00837.x<?supplied-pmid 14971804?>14971804 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="151" pm="."><plain>2.t JongGWvan der LindenPDBakkerEMvan der LelyNElandIAStrickerBHUnlicensed and off-label drug use in a paediatric ward of a general hospital in the NetherlandsEur J Clin Pharmacol200258429329710.1007/s00228-002-0479-912136376 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="152" pm="."><plain>3.HoppuKReflection: medicines for children–science alone is not enoughEur J Clin Pharmacol201369Suppl 1596310.1007/s00228-013-1487-7<?supplied-pmid 23640189?>23640189 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="153" pm="."><plain>4.KearnsGLAbdel-RahmanSMAlanderSWBloweyDLLeederJSKauffmanREDevelopmental pharmacology–drug disposition, action, and therapy in infants and childrenN Engl J Med2003349121157116710.1056/NEJMra035092<?supplied-pmid 13679531?>13679531 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="154" pm="."><plain>5.KrekelsEHDanhofMTibboelDKnibbeCAOntogeny of hepatic glucuronidation; methods and resultsCurr Drug Metab201213672874310.2174/138920012800840455<?supplied-pmid 22452455?>22452455 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="155" pm="."><plain>6.De CockRFPianaCKrekelsEHDanhofMAllegaertKKnibbeCAThe role of population PK-PD modelling in paediatric clinical researchEur J Clin Pharmacol201167Suppl 151610.1007/s00228-009-0782-9<?supplied-pmid 20340012?>20340012 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="156" pm="."><plain>7.BarrettJSDella Casa AlberighiOLaerSMeibohmBPhysiologically based pharmacokinetic (PBPK) modeling in childrenClin Pharmacol Ther2012921404910.1038/clpt.2012.64<?supplied-pmid 22669290?>22669290 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="157" pm="."><plain>8.KnibbeCADanhofMIndividualized dosing regimens in children based on population PKPD modelling: are we ready for it?Int J Pharm20114151–291410.1016/j.ijpharm.2011.02.056<?supplied-pmid 21376791?>21376791 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="158" pm="."><plain>9.KnibbeCAKrekelsEHDanhofMAdvances in paediatric pharmacokineticsExpert Opin Drug Metab Toxicol2011711810.1517/17425255.2011.539201<?supplied-pmid 21117982?>21117982 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="159" pm="."><plain>10.Food and Drug Administration US Department of Health and Human Services. </plain></SENT>
<SENT sid="160" pm="."><plain>Guidance for Industry Investigators and Reviewers. </plain></SENT>
<SENT sid="161" pm="."><plain>Exploratory IND Studies. </plain></SENT>
<SENT sid="162" pm="."><plain>January 2006. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf</ext-link>. </plain></SENT>
<SENT sid="163" pm="."><plain>Accessed 25 Aug 2014. </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="164" pm="."><plain>11.European Medicines Agency. </plain></SENT>
<SENT sid="165" pm="."><plain>ICH topic M3 (R2). </plain></SENT>
<SENT sid="166" pm="."><plain>Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. </plain></SENT>
<SENT sid="167" pm="."><plain>London: European Medicines Agency; Jul 2008. </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="168" pm="."><plain>12.LappinGKuhnzWJochemsenRKneerJChaudharyAOosterhuisBUse of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugsClin Pharmacol Ther200680320321510.1016/j.clpt.2006.05.008<?supplied-pmid 16952487?>16952487 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="169" pm="."><plain>13.SalehpourMPossnertGBryhniHSubattomole sensitivity in biological accelerator mass spectrometryAnal Chem200880103515352110.1021/ac800174j<?supplied-pmid 18422337?>18422337 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="170" pm="."><plain>14.CeelieIde WildtSNvan DijkMvan den BergMMvan den BoschGEDuivenvoordenHJEffect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trialJAMA2013309214915410.1001/jama.2012.148050<?supplied-pmid 23299606?>23299606 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="171" pm="."><plain>15.PathakCMKaurBKhandujaKL14C-urea breath test is safe for pediatric patientsNucl Med Commun201031983083510.1097/MNM.0b013e32833c3647<?supplied-pmid 20864821?>20864821 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="172" pm="."><plain>16.VuongLTBloodABVogelJSAndersonMEGoldsteinBApplications of accelerator MS in pediatric drug evaluationBioanalysis20124151871188210.4155/bio.12.173<?supplied-pmid 22943618?>22943618 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="173" pm="."><plain>17.LappinGShishikuraYJochemsenRWeaverRJGessonCBrian HoustonJComparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteersEur J Pharm Sci201143314115010.1016/j.ejps.2011.04.009<?supplied-pmid 21540108?>21540108 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="174" pm="."><plain>18.TozukaZKusuharaHNozawaKHamabeYIkushimaIIkedaTMicrodose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjectsClin Pharmacol Ther201088682483010.1038/clpt.2010.206<?supplied-pmid 21048707?>21048707 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="175" pm="."><plain>19.AllegaertKTibboelDComments on “shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats”J Pharmacol Exp Ther2006316296696710.1124/jpet.105.096024<?supplied-pmid 16428678?>16428678 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="176" pm="."><plain>20.van der MarelCDAndersonBJvan LingenRAHolfordNHPluimMAJansmanFGParacetamol and metabolite pharmacokinetics in infantsEur J Clin Pharmacol200359324325110.1007/s00228-003-0608-0<?supplied-pmid 12761605?>12761605 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="177" pm="."><plain>21.ZhouXJGarnerRCNicholsonSKisslingCJMayersDMicrodose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjectsJ Clin Pharmacol200949121408141610.1177/0091270009343698<?supplied-pmid 19776293?>19776293 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="178" pm="."><plain>22.van DuijnESandmanHGrossouwDMockingJACoulierLVaesWHAutomated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole rangeAnal Chem201486157635764110.1021/ac5015035<?supplied-pmid 25033319?>25033319 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="179" pm="."><plain>23.KleinMVVaesWHJFabriekBSandmanHMousDJWGottdangAThe 1 MV multi-element AMS system for biomedical applications at the Netherlands Organization for Applied Scientific Research (TNO)Nucl Instr Meth Phys Res B2013294141710.1016/j.nimb.2012.06.024 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="180" pm="."><plain>24.HigtonDYoungGTimmermanPAbbottRKnutssonMSvenssonLDEuropean Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometryBioanalysis20124222669267910.4155/bio.12.242<?supplied-pmid 23210650?>23210650 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="181" pm="."><plain>25.HopkinsCSUnderhillSBookerPDPharmacokinetics of paracetamol after cardiac surgeryArch Dis Child199065997197610.1136/adc.65.9.971<?supplied-pmid 2221970?>2221970 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="182" pm="."><plain>26.AndersonBJvan LingenRAHansenTGLinYCHolfordNHAcetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysisAnesthesiology20029661336134510.1097/00000542-200206000-00012<?supplied-pmid 12170045?>12170045 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="183" pm="."><plain>27.WalsonPDHalvorsenMEdgeJCasavantMJKelleyMTPharmacokinetic comparison of acetaminophen elixir versus suppositories in vaccinated infants (aged 3 to 36 months): a single-dose, open-label, randomized, parallel-group designClin Ther201335213514010.1016/j.clinthera.2012.12.016<?supplied-pmid 23351277?>23351277 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="184" pm="."><plain>28.MooijMGde KoningBAHuijsmanMLde WildtSNOntogeny of oral drug absorption processes in childrenExpert Opin Drug Metab Toxicol20128101293130310.1517/17425255.2012.698261<?supplied-pmid 22686526?>22686526 </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="185" pm="."><plain>29.RatnapalanSBonaNChandraKKorenGPhysicians’ perceptions of teratogenic risk associated with radiography and CT during early pregnancyAJR Am J Roentgenol200418251107110910.2214/ajr.182.5.1821107<?supplied-pmid 15100102?>15100102 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="186" pm="."><plain>30.de WildtSNTaguchiNKorenGUnintended pregnancy during radiotherapy for cancerNat Clin Pract Oncol20096317517810.1038/ncponc1320<?supplied-pmid 19174775?>19174775 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="187" pm="."><plain>31.MaedaKIkedaYFujitaTYoshidaKAzumaYHaruyamaYIdentification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing studyClin Pharmacol Ther201190457558110.1038/clpt.2011.142<?supplied-pmid 21832990?>21832990 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="188" pm="."><plain>32.GorskiJCJonesDRHaehner-DanielsBDHammanMAO’MaraEMJrHallSDThe contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycinClin Pharmacol Ther199864213314310.1016/S0009-9236(98)90146-1<?supplied-pmid 9728893?>9728893 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
